Humasis Co. Ltd. announced that it has received KRW 8.5 billion in funding from KB Securities Co., Ltd., Investment Arm, Korea Securities Finance Corporation, Investment Arm, Samsung Securities Co. Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Hanyang Securities Co. Ltd., Investment Arm, and other investors
August 23, 2018
Share
On August 24, 2018, Humasis Co. Ltd. (KOSDAQ:A205470) closed the transaction.
Humasis Co Ltd is a Korea-based company principally engaged in the manufacture and sale of in vitro diagnostic devices. The Company is engaged in the manufacture and sale of immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, cancer marker test devices and other products. In addition, the Company is engaged in the research and development of biomaterials and other products. The Company sells its products within domestic market and to overseas markets. The Company was established in 2000 and is located in Gunpo-si, Gyeonggi-do, South Korea.
Humasis Co. Ltd. announced that it has received KRW 8.5 billion in funding from KB Securities Co., Ltd., Investment Arm, Korea Securities Finance Corporation, Investment Arm, Samsung Securities Co. Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Hanyang Securities Co. Ltd., Investment Arm, and other investors
HUMASIS CO. LTD. 
